These results are in line with previous reports demonstrating that simultaneous inhibition of the PI3K/AKT/mTOR and MAPK/ERK pathways can produce synergistic antitumor effects in melanoma models, offering a potential mechanistic explanation for the enhanced efficacy observed with combination therapy [35]. This evidence concerns the gene MTOR and melanoma.